References
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA A Cancer J Clin. 2020;70(1):7–30.
- Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136–1152.
- Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA A Cancer J Clin. 2019;69(5):363–385.
- Finn L, Sproat L, Heckman MG, et al. Epidemiology of adult acute myeloid leukemia: impact of exposures on clinical phenotypes and outcomes after therapy. Cancer Epidemiol. 2015;39(6):1084–1092.
- Terashima AV, Mudumana SP, Drummond IA. Odd skipped related 1 is a negative feedback regulator of nodal-induced endoderm development. Dev Dyn. 2014;243(12):1571–1580.
- Zhang Y, Yuan Y, Liang P, et al. OSR1 is a novel epigenetic silenced tumor suppressor regulating invasion and proliferation in renal cell carcinoma. Oncotarget. 2017;8(18):30008–30018.
- Wang Y, Lei L, Xu F, et al. Reduced expression of odd-skipped related transcription factor 1 promotes proliferation and invasion of breast cancer cells and indicates poor patient prognosis. Oncol Lett. 2020;20(3):2946–2954.
- Zhang F, Jiang Z. Downregulation of OSR1 promotes colon adenocarcinoma progression via FAK-mediated AKT and MAPK signaling. Onco Targets Ther. 2020;13:3489–3500.
- Chen W, Wu K, Zhang H, et al. Odd-skipped related transcription factor 1 (OSR1) suppresses tongue squamous cell carcinoma migration and invasion through inhibiting NF-κB pathway. Eur J Pharmacol. 2018;839:33–39.
- Milella M, Kornblau SM, Estrov Z, et al. Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest. 2001;108(6):851–859.
- Espinoza JL, Elbadry MI, Taniwaki M, et al. The simultaneous inhibition of the mTOR and MAPK pathways with Gnetin-C induces apoptosis in acute myeloid leukemia. Cancer Lett. 2017;400:127–136.
- Huang X, Schwind S, Santhanam R, et al. Targeting the RAS/MAPK pathway with miR-181a in acute myeloid leukemia. Oncotarget. 2016;7(37):59273–59286.
- Otani K, Dong Y, Li X, et al. Odd-skipped related 1 is a novel tumour suppressor gene and a potential prognostic biomarker in gastric cancer. J Pathol. 2014;234(3):302–315.
- Licht JD, Sternberg DW. The molecular pathology of acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2005;2005(1):137–142.
- Wang Y, Lei L, Zheng Y-W, et al. Odd-skipped related 1 inhibits lung cancer proliferation and invasion by reducing Wnt signaling through the suppression of SOX9 and β-catenin. Cancer Science. 2018; 109(6):1799–1810.
- Hiraoka K, Hayashi T, Kaneko R, et al. SOX9-mediated upregulation of LGR5 is important for glioblastoma tumorigenicity. Biochem Biophys Res Commun. 2015;460(2):216–221.
- Hirsch D, Barker N, McNeil N, et al. LGR5 positivity defines stem-like cells in colorectal cancer. Carcinogenesis. 2014;35(4):849–858.
- Xu L, Lin W, Wen L, et al. Lgr5 in cancer biology: functional identification of Lgr5 in cancer progression and potential opportunities for novel therapy. Stem Cell Res Ther. 2019;10(1):219.
- Cosgun KN, Deb G, Yang X, et al. Lgr5 enables positive B-Cell selection and tumor-initiation in B-cell malignancies. Blood. 2018;132(Supplement 1):547–547.
- Kim S-H, Kim K-H, Yoo B-C, et al. Induction of LGR5 by H2O2 treatment is associated with cell proliferation via the JNK signaling pathway in colon cancer cells. Int J Oncol. 2012;41(5):1744–1750.
- Gao H-e, Sun Y, Ding Y-h, et al. Antineoplastic effects of CPPTL via the ROS/JNK pathway in acute myeloid leukemia. Oncotarget. 2017;8(24):38990–39000.
- Lin X, Fang Q, Chen S, et al. Heme oxygenase-1 suppresses the apoptosis of acute myeloid leukemia cells via the JNK/c-JUN signaling pathway. Leuk Res. 2015;39(5):544–552.
- Zhou P, Chen X, Li M, et al. Overexpression of PRDM5 promotes acute myeloid leukemia cell proliferation and migration by activating the JNK pathway. Cancer Med. 2019;8(8):3905–3917.